Altimmune Inc is a late clinical-stage biopharmaceutical company developing therapies for patients with serious liver diseases. The Company's key candidate, pemvidutide, is a dual-action therapy targeting both glucagon and GLP-1 receptors in a balanced 1:1 ratio in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), alcohol use disorder (AUD), and alcohol-associated liver disease (ALD). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.
Last trade$1.56
Day change-$0.005 (-0.32%)
Day range$1.50 – $1.60
Volume2,569,790
Market cap$304M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$303.56M
Price / earnings
—
Price / book
0.68×
Price / sales
11,675.37×
EV / sales
11,910.02×
EV / EBITDA
-2.69×
Profitability
Earnings per share
-$0.54
Return on assets
-21.11%
Return on equity
-23.59%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0.08×
Current ratio
23.93×
Quick ratio
23.93×
Cash ratio
2.51×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$102.47M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for ALT, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$0
$0
$0
$26K
$5K
$5K
$5K
$5K
Cost of revenue
$0
$0
$0
$0
$0
$0
$0
$0
Gross profit
$0
$0
$0
$26K
$5K
$5K
$5K
$5K
Selling, general and administrative
$8.69M
$7.57M
$8.05M
$10.51M
$5.9M
$5.69M
$5.99M
$5.09M
Research and development
$27.02M
$18.66M
$16.19M
$18.41M
$14.96M
$17.24M
$15.83M
$19.78M
Total operating expenses
$35.71M
$26.23M
$24.24M
$28.92M
$20.86M
$22.93M
$21.82M
$24.87M
Operating income
-$35.71M
-$26.23M
-$24.24M
-$28.89M
-$20.86M
-$22.92M
-$21.82M
-$24.87M
Interest expense
-$1.12M
-$1.1M
-$1.07M
-$876K
-$495K
-$264K
-$1K
-$1K
Income before taxes
-$31.61M
-$22.83M
-$22.56M
-$27.36M
-$19.01M
-$22.15M
-$20.26M
-$23.18M
Income taxes
$0
$0
$0
$0
$0
$0
-$681K
$0
Net income
-$31.61M
-$22.83M
-$22.56M
-$27.36M
-$19.01M
-$22.15M
-$19.58M
-$23.18M
Net income attributable to common shareholders
-$31.61M
-$22.83M
-$22.86M
-$27.36M
-$19.01M
-$22.15M
-$19.61M
-$23.18M
EBITDA
-$35.69M
-$26.21M
-$24.22M
-$28.87M
-$20.83M
-$22.89M
-$21.79M
-$24.83M
Basic earnings per share
-$0.15
-$0.12
-$0.18
-$0.26
-$0.21
-$0.27
-$0.26
-$0.33
Diluted earnings per share
-$0.15
-$0.12
-$0.18
-$0.26
-$0.21
-$0.27
-$0.26
-$0.33
Recent news
Company coverage with links to the original publishers.
Altimmune reported a Q3 2026 loss of 15 cents per share, missing consensus estimates by one cent. R&D expenses surged 80.6% to $27 million due to ongoing pemvidutide clinical studies. The company has $480 million in cash expected to fund operations into 2029. Stock declined 17% following the announcement due to concerns over rising development costs and funding uncertainty for the planned phase III AUD program.
Altimmune announced that its RECLAIM Phase 2 trial data for pemvidutide, a dual glucagon/GLP-1 receptor agonist, in treating alcohol use disorder (AUD) has been accepted as a late-breaking oral presentation at AASLD The Liver Meeting 2026. The trial met its primary endpoint of reducing heavy drinking days and key secondary endpoints. The company is scheduled to meet with the FDA in December for an End-of-Phase 2 meeting to discuss Phase 3 registrational plans.
The MASH (Metabolic Dysfunction-Associated Steatohepatitis) market is rapidly expanding with over 180 companies developing 200+ pipeline therapies. Two drugs have been approved: REZDIFFRA (resmetirom) by Madrigal Pharmaceuticals and LIPAGLYN/BILYPSA (saroglitazar magnesium) by Zydus Lifesciences. The competitive landscape is intensifying with emerging mechanisms of action including FGF21 replacements, GLP-1 receptor agonists, and dual glucagon/GLP-1 agonists, with approximately 5+ drugs in late-stage development and 100+ in mid and early stages.
Novo Nordisk is expanding semaglutide into new indications like MASH and obesity-related conditions to diversify revenue beyond its core GLP-1 franchise. However, the company faces significant competitive pressure from Eli Lilly's broad incretin portfolio expansion and other competitors in the MASH market. Novo's stock has underperformed the industry year-to-date, trading at a discount valuation with a Hold rating.
Altimmune reported a Q2 2026 loss of 12 cents per share, beating the consensus estimate of 15 cents, with no revenues as the company lacks marketed drugs. R&D expenses rose 8.2% to $18.7 million, primarily due to ongoing MASH clinical studies. The company's cash position strengthened to $519 million, supporting operations into 2029. Shares have gained 14.2% over the past month, outperforming the S&P 500, though the stock carries a Zacks Rank #3 (Hold) rating with an overall VGM Score of F.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.